Screener
Halozyme Therapeutics HALO Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill.
The source filing: Halozyme Therapeutics’s 10-K, filed February 17, 2026.
- Filed
- Feb 17, 2026, 4:08 PM EST
- Fiscal year
- FY2025
- Accession
- 0001159036-26-000024
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Amortization of intangibles | 76,662 | 71,049 | 73,773 |
| Research and development | 81,490 | 79,048 | 76,363 |
| Selling, general and administrative | 207,092 | 154,335 | 149,182 |
| Impairment of intangible asset | 48,700 | — | — |
| Acquired in-process research and development expense | 284,887 | — | — |
| Total operating expenses | 927,605 | 463,849 | 491,679 |
| Operating income | 469,006 | 551,475 | 337,574 |
| Other income (expense) |
Item 16.Form 10-K Summary
FAQ
- What is Halozyme Therapeutics's impairment charges?
- Halozyme Therapeutics (HALO) reported impairment charges of $12.18M in Q4 2025.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Halozyme Therapeutics's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude